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INTRODUCTION 
 
Valsartan is a drug that lowers blood pressure and is as effective as enalapril, lisinopril and 
amlodipine in the treatment of mild to moderate hypertension. Valsartan is available as tablets for 
oral administration, containing 40 mg, 80 mg, 160 mg or 320 mg of valsartan. 
Literature survey revealed that valsartan is not yet official in any of the pharmacopoeia. There are 
various analytical methods with UV, HPLC, LC-MS and other analytical techniques for determination 
of valsartan. In recent years many methods have been developed for the determination of valsartan 
in pharmaceutical dosage forms based on HPLC. 
The focus of present study was to develop and validate a rapid and economical HPLC method for 
the determination of valsartan in tablet dosage form. 
APPARATUS  
 
The analysis was carried on VARIAN HPLC system consisted of: tertiary pump 9012 and 9050 
UV/VIS detector. Column MERCK Lichrospher 100 RP Selekt B (250 mm x 4,0 and particle size 5 
μm) was used for separation. 
Solubility of the tablets is determined by the solubility apparatus ERVEKA DT 700 /1000 LH ZT 302   
UV/VIS – spectrophotometer Cary 100 Scan Varian is used to determine the optimal wavelength. 
RESULTS AND DISCUSSION 
 
To determine the optimum mobile phase, it is determined the absorbance of standard solution with 
different mobile phases. Solution of 10 mM NH4H2PO4 combined with ACN and methanol. Fig. 1a 
provides measurement results with mobile phase ACN:puffer in ratio 70:30, 60:40, 50:50 and 40:60, 
and in Fig. 1b results of measuring the mobile phase methanol: puffer  in ratio 70:30, 60:40, and 
50:50. 
Fig. 1 Retention time and absorbance change by changing of mobile phase in ratio: 
 a)ACN:buffer; b) methanol:buffer 
Fig. 3 Solubility of valsartan in a different medium for different times  
 
 
Fig. 2 Absorbance change by changing of wavelength:   
a)190-350 nm with UV; b) 210-250 nm with HPLC  
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To determine the optimal wavelength was recorded UV spectrum of valsartan in the area 
of ​​190-350 nm, and then in the highest apsorbances of 210-250 nm it is measured HPLC 
valsartan standard under the prescribed mobile phase (ACN: puffer in ratio70:30). 
Table 1. Accuracy of the Method 
a 
To determine the optimal medium for the solubility of valsartan are used three 
different media: phosphate buffer 6.8, acetate buffer 4.5 and 0,1 M HCl. 
The amount of each medium was 1000 mL, the temperature of fluid 37 0,5oC, the 
number of rotation 50 rpm, and the time of sampling 15, 30 and 45 min.  
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VALIDATION OF THE METHOD 
 
According to ICH regulations, validation of analytical method for determining 
the parameter content includes the following parameters: specificity, linearity, 
accuracy, precision and range of the method. Besides these parameters we 
chose LOD and LQD.  
 
Added 
(μg/mL) 
Found 
(μg/mL) 
Recovery 
(%) 
Mean 
recovery 
(%) 
RSD (%) 
128 129,21 100,95  
99,37 
 
1,49 128 125,45 98,01 
128 126,92 99,16 
160 158,98 99,36  
99,08 
 
0,71 160 159,36 99,60 
160 157,25 98,28 
192 193,33 100,69  
100,53 
 
1,23 192 195,21 101,67 
192 190,49 99,21 
CONCLUSION 
  
It is proposed new method for the determination of valsartan in 
pharmaceutical dosage forms. Experimentally are determined the optimal 
chromatographic conditions, the optimal medium and optimal time for 
sampling. The proposed method is validated according to ICH regulations. 
The following  parameters are determined: specificity, linearity, range, limit of 
detection, limit of quantification, precision and accuracy. In its method range 
there is great linearity with correlation coefficient R=0,999, limit of detection 
LOD=1,7 μg/mL and limit of quantification LQD=5,1 μg/mL. The method is 
characterized by high accuracy which is determined by three standard 
additions to the placebo. Repeatability and intermediate precision are 
determined. The% RSD values ​​for ripitability, intraday and interday precision 
were <1%. The retention time is 2,7 min and the method is very simple and 
quick. 
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